PFHxS

PFHxS reaches drinking water predominantly through three legacy pathways. (1) Aqueous film-forming foam (AFFF) release at military installations and civilian airports is the dominant signature — the PFHxS top-occurrence list reads like an AFB roster: Stratmoor Hills and Security Water District in Colorado Springs (155.5 and 132.0 ppt) sit downstream of the Peterson Space Force Base / former Peterson AFB AFFF impact area; Fort Campbell on the Kentucky/Tennessee line (30.1 ppt at both on-base and county-supply systems); Wright-Patterson AFB in Ohio (23.2 ppt across 22 of 22 tests); Camp Pendleton North in California (22.2 ppt, 156 of 162 tests); and Fort Riley, Kansas (18.8 ppt). (2) 3M-era PFOS-based Scotchgard manufacturing and use, of which PFHxS was a minor synthesis impurity and co-precursor — Bemidji, MN (84.2 ppt over 51 tests) sits within the Bemidji Regional Airport AFFF and 3M Cottage Grove regional influence area, and the Oakdale, MN system (10.6 ppt) traces directly to 3M Cottage Grove. (3) Industrial discharges from chrome plating, semiconductor fabrication, and other industries where PFHxS replaced PFOS as a mist suppressant in the mid-2000s — Hannah Heights HOA in Friday Harbor, WA (725.9 ppt average across 2 of 4 tests) and Oatman Water in Scottsdale, AZ (710.0 ppt) are the two highest PFHxS detections in the national occurrence dataset and reflect localized point-source impacts. Major municipal systems exceeding the 10 ppt federal MCL include the City of Greensboro, NC (11.1 ppt serving 318,057 people) and Fayetteville Public Works Commission, NC (10.7 ppt serving 214,137 people) — both within the Cape Fear basin Chemours influence area.

EPA's 2023 IRIS toxicological review identifies two co-critical endpoints for PFHxS: decreased serum free thyroxine (T4) in adults and reduced antibody response to childhood vaccines (the immune-developmental endpoint). The chronic Reference Dose is 4×10⁻⁷ mg/kg/day — orders of magnitude lower than EPA's PFHxA RfD of 5×10⁻⁴ mg/kg/day, which is why the surrogate-derived health benchmarks for long-chain PFSAs sit in the single-digit-ppt range versus thousand-ppt for PFHxA. Commonly listed PFHxS health concerns are cancer, immune system damage, hormone disruption, harm to fetal growth and child development, and harm to the liver. PFHxS has not been formally classified as a carcinogen by IARC or NTP, which is why the federal MCLG is set at 10 ppt rather than zero — the MCLG-of-zero approach EPA used for PFOA and PFOS reflects their IARC Group 1 cancer classifications, and PFHxS does not yet share that designation. PFHxS bioaccumulates: serum elimination half-life in humans is among the longest of any PFAS measured, with Olsen 2007 reporting a median of 8.5 years (range roughly 3-30 years across the 3M production-worker cohort). Detectable PFHxS appears in essentially 100% of U.S. adults sampled by NHANES, and serum levels have declined more slowly than PFOS since the 2002 3M phaseout.

PFHxS responds well to the same treatment technologies used for PFOS and other long-chain PFSAs: granular activated carbon (GAC), anion exchange resin, and high-pressure membranes (reverse osmosis, nanofiltration). The sulfonate head group provides strong electrostatic affinity for anion exchange media, and the 6-carbon perfluorinated tail provides adequate hydrophobic adsorption onto GAC — PFHxS breakthrough on GAC occurs later than the short-chain PFCAs (PFBA, PFHxA) but earlier than PFOS, and design loading rates fall between those two reference points. Conventional treatment processes — coagulation, sand filtration, disinfection, UV, and ozonation — do not remove PFHxS. Boiling concentrates rather than removes it. NSF/ANSI 53 and NSF P473 certify point-of-use filters for general PFAS reduction; NSF/ANSI 58 covers RO systems. Utilities targeting the 10 ppt federal MCL with GAC, AIX, or RO will incidentally control PFHxS to well below the federal Hazard Index threshold and will simultaneously reduce the other long-chain PFSAs (PFOS, PFHpS) that share treatment behavior; the surrogate-derived 0.001-ppt health benchmark sits below analytical reporting limits and is not operationally verifiable.